Latest News

2026-08-04

HbA1c Reduction of Up to 2.78%: Hengrui Pharma Reports Positive Topline Data from Phase 3 Trial in China of GLP-1/GIP Dual Receptor Agonist Ribupatide Injection in Adults with Type 2 Diabetes Inadequately Controlled with Oral Antidiabetic Treatment